Citigroup Inc. reduced its position in Privia Health Group, Inc. (NASDAQ:PRVA – Free Report) by 25.9% in the 3rd quarter, Holdings Channel reports. The fund owned 54,823 shares of the company’s stock after selling 19,201 shares during the period. Citigroup Inc.’s holdings in Privia Health Group were worth $1,261,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. grew its stake in shares of Privia Health Group by 201.7% during the 2nd quarter. BlackRock Inc. now owns 13,938,867 shares of the company’s stock valued at $363,944,000 after buying an additional 9,319,052 shares during the period. Durable Capital Partners LP purchased a new stake in shares of Privia Health Group during the 2nd quarter valued at $237,364,000. Vanguard Group Inc. grew its stake in shares of Privia Health Group by 7.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,824,724 shares of the company’s stock valued at $164,331,000 after buying an additional 321,734 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Privia Health Group by 1.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 4,040,027 shares of the company’s stock valued at $92,921,000 after buying an additional 62,543 shares during the period. Finally, Principal Financial Group Inc. grew its stake in shares of Privia Health Group by 3.3% during the 3rd quarter. Principal Financial Group Inc. now owns 3,505,260 shares of the company’s stock valued at $80,621,000 after buying an additional 111,538 shares during the period. 92.40% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on PRVA shares. Bank of America cut shares of Privia Health Group from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $27.00 to $21.00 in a research note on Thursday, February 22nd. JMP Securities started coverage on shares of Privia Health Group in a research report on Wednesday, December 6th. They set an “outperform” rating and a $27.00 price target for the company. Jefferies Financial Group started coverage on shares of Privia Health Group in a research report on Monday. They set a “buy” rating and a $25.00 price target for the company. Finally, JPMorgan Chase & Co. decreased their price target on shares of Privia Health Group from $43.00 to $38.00 and set an “overweight” rating for the company in a research report on Friday, November 17th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.18.
Check Out Our Latest Stock Report on Privia Health Group
Privia Health Group Price Performance
Shares of PRVA stock opened at $20.00 on Tuesday. Privia Health Group, Inc. has a 12 month low of $19.17 and a 12 month high of $30.15. The firm has a market capitalization of $2.36 billion, a P/E ratio of 64.52, a P/E/G ratio of 1.92 and a beta of 0.80. The company’s fifty day moving average price is $21.68 and its two-hundred day moving average price is $22.64.
Insiders Place Their Bets
In other news, Director William M. Sullivan sold 9,951 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $23.03, for a total value of $229,171.53. Following the sale, the director now owns 5,464,533 shares in the company, valued at approximately $125,848,194.99. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director William M. Sullivan sold 12,000 shares of the company’s stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $23.97, for a total value of $287,640.00. Following the sale, the director now owns 5,474,484 shares in the company, valued at approximately $131,223,381.48. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director William M. Sullivan sold 9,951 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $23.03, for a total transaction of $229,171.53. Following the completion of the sale, the director now owns 5,464,533 shares in the company, valued at approximately $125,848,194.99. The disclosure for this sale can be found here. 44.80% of the stock is currently owned by company insiders.
About Privia Health Group
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Read More
Want to see what other hedge funds are holding PRVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Privia Health Group, Inc. (NASDAQ:PRVA – Free Report).
Receive News & Ratings for Privia Health Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Privia Health Group and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: americanbankingnews.com
